Thursday, 26 Apr 2018

You are here

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

They studied 2 large primary care sites - one underwent the intervention, the other/control, did not. The gout management plan ("intervention") included education of the intervention staff and EMR to assess outcomes; 1) percent of gout patients treated with urate lowering therapy; 2) percent of treated patients monitored with serum urate; and 3) percent of treated patients at target serum urate ≤ 6.0 mg/dl. The intervention site providers received monthly performance reports compared to their peers.

At 6 months, the intervention site significantly improved all 3 gout performance measures.

  • ULT use increased from 54.4 to 61.1%, OR 1.19 (95% CI 1.08, 1.31 and p-value <0.001);
  • Monitoring increased from 56.1 to 79.2% OR 1.52 (95% CI 1.24, 1.87 and P-value <0.001);
  • Achieving a T2T goal (< 6.0)  increased from 26.8 to 43.3% OR 1.43 (95% CI 1.16, 1.77 and p-value <0.001.

At 6 months gout patients at the intervention site were 3.5 times more likely to be monitored and 2 times more likely to achieve their urate goal (p-value <0.001) than control site patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)